CheckMate 214 Exploratory Biomarker Analysis: Predicting Response to Nivolumab Plus Ipilimumab in Advanced RCC

From Clinical Care Options (CCO), an expert video webinar on immunotherapy and targeted agents in RCC treatment

Elizabeth R. Plimack, MD, MS
Program Director Rana R. McKay, MD Brian Rini, MD, FASCO Physicians: maximum of 0.75 AMA PRA Category 1 Credits™ Released: November 18, 2021 Expired: November 17, 2022

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

Maria E. Arcila, MD Released: November 16, 2021

Short slideset on second-generation TRK inhibitors selitrectinib and repotrectinib in NTRK fusion+ solid tumors, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Downloadable slideset based on discussion by Drs Plimack, McKay, and Rini on treatment options for patients with RCC, from Clinical Care Options (CCO)

Rana R. McKay, MD Elizabeth R. Plimack, MD, MS Brian Rini, MD, FASCO Released: November 1, 2021